fiercepharma.com

Imdelltra DLL3 therapy posts overall survival win for first-line small cell lung cancer

Amgen logoAmgen
Sig3.54Sen+5.53Env0.00Soc+3.75Gov0.00

Amgen’s DLL3 T‑cell engager Imdelltra showed an overall survival win in the phase 3 DeLLphi‑305 trial for first-line small cell lung cancer, supporting earlier use against an aggressive disease. The study builds on DeLLphi‑303 ES‑SCLC maintenance data with a 25.3‑month median OS and a full nod converted from earlier go-ahead last year after DeLLphi‑304.

Coverage (3)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro